<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053339</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-49903</org_study_id>
    <secondary_id>CDR0000269409</secondary_id>
    <nct_id>NCT00053339</nct_id>
  </id_info>
  <brief_title>Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer</brief_title>
  <official_title>Phase III Randomized Study of Trastuzumab (Herceptin) With or Without Tamoxifen in Women With Progressive, Stage IV, Estrogen or Progesterone Receptor- and HER2/Neu-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill&#xD;
      them or deliver tumor-killing substances to them without harming normal cells. Estrogen can&#xD;
      stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast&#xD;
      cancer by blocking the uptake of estrogen. Combining trastuzumab with tamoxifen may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of trastuzumab with or&#xD;
      without trastuzumab in treating women who have invasive stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare time to progression in women with progressive, stage IV, estrogen or&#xD;
           progesterone receptor- and HER2/neu-positive breast cancer treated with trastuzumab&#xD;
           (Herceptin) with or without tamoxifen.&#xD;
&#xD;
        -  Correlate response with type of measurement (immunohistochemistry or fluorescent in situ&#xD;
           hybridization) of HER2/neu expression in patients treated with these regimens.&#xD;
&#xD;
        -  Compare objective response rate (complete or partial response) in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to prior adjuvant&#xD;
      treatment (yes vs no), ECOG performance status (0-1 vs 2), and prior aromatase inhibitor&#xD;
      treatment (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive trastuzumab as in arm I and oral tamoxifen once daily on days&#xD;
           1-21.&#xD;
&#xD;
      In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this&#xD;
      study within 28 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was not activated.&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <arm_group>
    <arm_group_label>trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.&#xD;
Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients are followed every 3 months for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trastuzumab + tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.&#xD;
In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients are followed every 3 months for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <arm_group_label>trastuzumab + tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>trastuzumab</arm_group_label>
    <arm_group_label>trastuzumab + tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive stage IV breast cancer&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
          -  HER2/neu positive (3+ by immunohistochemical [IHC] assay or fluorescent in situ&#xD;
             hybridization [FISH])&#xD;
&#xD;
          -  Estrogen receptor or progesterone receptor positive&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Must have disease progression within 6 months of initiation of tamoxifen (administered&#xD;
             in the adjuvant or metastatic setting) or during aromatase inhibitor therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF normal by MUGA&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception during and for at least&#xD;
             2 months after study completion&#xD;
&#xD;
          -  No other concurrent active malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  Patients who have completed prior therapy and are at less than 30% risk of relapse are&#xD;
             not considered to have an active malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin) in the adjuvant or metastatic setting&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen in the metastatic setting&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 prior hormonal therapy regimen for metastatic disease&#xD;
&#xD;
          -  Prior aromatase inhibitor therapy administered in the first-line metastatic or&#xD;
             adjuvant setting is allowed provided there is disease progression on tamoxifen&#xD;
&#xD;
          -  No other concurrent hormonal therapy except the following:&#xD;
&#xD;
          -  Steroids for adrenal failure&#xD;
&#xD;
          -  Hormones for nondisease-related conditions (e.g., insulin for diabetes)&#xD;
&#xD;
          -  Intermittent use of dexamethasone as an antiemetic&#xD;
&#xD;
          -  Vaginal estrogen (or EstringÂ®) for vaginal dryness&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent palliative radiotherapy except whole brain irradiation for CNS disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
&#xD;
          -  No concurrent cardioprotective drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne E. Mortimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sentara Cancer Center</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

